Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
January 25th, 2008
Barr Pharmaceuticals, Inc. (NYSE:BRL) announced that its subsidiary, Barr Laboratories, has initiated a challenge of the patents listed by Sanofi-Aventis U.S. LLC in connection with its Eloxatin(R) (Oxaliplatin Aqueous Solution), 5mg/mL Injectable. Barr filed an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Eloxatin product with the U.S. Food & Drug Administration (FDA), and following FDA notification of the application's acceptance for filing, the Company notified the New Drug Application (NDA) and patent owner. On January 4, 2008, Sanofi-Aventis U.S. LLC, Sanofi-Aventis and Debiopharm S.A. filed suit...
Source: Medical Patent Business Week (2008-01-25)
|
